Summary of treatment-emergent adverse events. Multiple adverse events for each subject are counted once within each unique category
| System | Adverse event | Number of subjects with events (percentage) | |
| Placebo (n=14) | SRT2104 (n=15) | ||
| Immune system | Any event | 1 (7%) | 0 |
| Seasonal allergy | 1 (7%) | 0 | |
| Vascular | Any event | 0 | 2 (13%) |
| Flushing | 0 | 2 (13%) | |
| General | Any event | 2 (14%) | 3 (20%) |
| Fatigue | 1 (7%) | 1 (7%) | |
| Flu-like illness | 0 | 1 (7%) | |
| Asthenia | 1 (7%) | 0 | |
| Malaise | 0 | 1(%) | |
| Infections | Any event | 3 (21%) | 1 (7%) |
| Nasopharyngitis | 3 (21%) | 0 | |
| Upper respiratory tract infection | 0 | 1 (7%) | |
| Renal and urinary disorders | Any event | 1 (7%) | 0 |
| Dysuria | 1 (7%) | 0 | |
| Any event | - | 11 (79%) | 14 (93%) |
| Injury, poisoning and procedural complications | Any event | 3 (21%) | 1 (7%) |
| Contusion | 1 (7%) | 0 | |
| Muscle strain | 1 (7%) | 0 | |
| Nail injury | 0 | 1 (7%) | |
| Postprocedure discomfort | 1 (7%) | 0 | |
| Neurological | Any event | 1 (7%) | 7 (47%) |
| Headache | 1 (7%) | 5 (33%) | |
| Paraesthesia | 0 | 1 (7%) | |
| Lethargy | 0 | 1 (7%) | |
| Gastrointestinal | Any event | 4 (29%) | 8 (53%) |
| Diarrhoea | 2 (14%) | 4 (27%) | |
| Nausea | 1 (7%) | 2 (13%) | |
| Upper abdominal pain | 0 | 1 (7%) | |
| Dyspepsia | 0 | 2 (13%) | |
| Abdominal discomfort | 0 | 1 (7%) | |
| Constipation | 1 (7%) | 0 | |
| Frequent bowel motions | 0 | 1 (7%) | |
| Immune system | Any event | 1 (7%) | 0 |
| Seasonal allergy | 1 (7%) | 0 | |
| Vascular | Any event | 0 | 2 (13%) |
| Flushing | 0 | 2 (13%) | |
| General | Any event | 2 (14%) | 3 (20%) |
| Fatigue | 1 (7%) | 1 (7%) | |
| Flu-like illness | 0 | 1 (7%) | |
| Asthenia | 1 (7%) | 0 | |
| Malaise | 0 | 1(%) | |
| Infections | Any event | 3 (21%) | 1 (7%) |
| Nasopharyngitis | 3 (21%) | 0 | |
| Upper respiratory tract infection | 0 | 1 (7%) | |
| Renal and urinary disorders | Any event | 1 (7%) | 0 |
| Dysuria | 1 (7%) | 0 | |